- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8th - - Data highlighting decreased transfusion requirements for patients treated with...
Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...
- MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen - - Targeting enrollment of 180 symptomatic...
View all news releases
Building Momentum for Patients with Myelofibrosis – Q4 2019
View All Presentations
Location: Orlando, FL Visit Sierra Oncology’s booth #1066 to speak with our team of experts! To schedule a meeting, email firstname.lastname@example.org
View all events and webcasts
James Smith, Vice President Corporate Affairs
Sign up for investor alerts